Yang Yao1, Xiangxia Miao2, Donglie Zhu3, Dongmin Li4, Ying Zhang5, Chengyan Song5, Kaige Liu6. 1. Department of Central Laboratory, the First Affiliated Hospital, Xi'an Medical University, Xi'an, Shaanxi, 710077, PR China. 2. Clinical Medicine (three-year program) of Postgrade 2016, Xi'an Medical University, Xi'an, Shaanxi, 710021, PR China. 3. Department of Hepatobiliary Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, 710032, PR China. 4. Department of Biochemistry and Molecular Biology, School of Basic Medical Science, Xi'an Jiaotong University Health Science Center, Xi'an, Shaanxi, 710061, PR China. 5. Clinical Medicine (three-year program) of Postgrade 2017, Xi'an Medical University, Xi'an, Shaanxi, 710021, PR China. 6. Department of Gastroenterology, the First Affiliated Hospital, Xi'an Medical University, Xi'an, Shaanxi, 710077, PR China. kaigeliu007@163.com.
Abstract
AIM: The prevalence of non-alcoholic fatty liver disease (NAFLD) is rapidly increasing worldwide. A number of researchers have studied the relationship between Insulin-like growth factor-1(IGF-1) and NAFLD. However, the results are controversial. This meta-analysis, aimed to systemically evaluate the correlation between IGF-1 and NAFLD. METHODS: We searched for four online databases: PubMed, Web of Science, Embase and CNKI up to Feb 2018. We then applied a random-effects model to evaluate the overall effect sizes by calculating Standard mean difference (SMD) and its 95% confidence intervals (CIs). RESULTS: Twelve articles were included in this meta-analysis. The pooled analysis showed that the level of IGF-1 in the control group was significantly higher than that in the NAFLD group. (SMD: 1.00, 95% CI: 0.54-1.46, P < 0.00001). However, significant heterogeneity was discovered among the included studies (P < 0.00001, I2 = 96%). Then a series of subgroup analyses were performed. Compared to the nonalcoholic steatohepatitis (NASH) group, the level of IGF-1 was significantly higher in the Non- or probable-NASH group (SMD: 1.42, 95% CI: 0.25-2.58, P = 0.02). The level of IGF-1 in patients with increased insulin resistance (SMD: 0.49; 95% CI: 0.36-0.63; P < 0.00001) and high Body Mass Index (SMD: 0.50; 95% CI: 0.22-0.79; P < 0.05) were significantly lower than healthy control. In addition, the same conclusion were found in studies carried out in Asia and Europe (Asia: SMD: 0.69, 95% CI: -0.29-1.66, P = 0.17; Europe: SMD: 0.89, 95% CI: 0.41-1.38, P < 0.05). CONCLUSION: The level of IGF-1 is down-regulated in NAFLD patients compared to healthy controls, suggesting that IGF-1 might be used as a potential biomarker and therapeutic target for NAFLD.
AIM: The prevalence of non-alcoholic fatty liver disease (NAFLD) is rapidly increasing worldwide. A number of researchers have studied the relationship between Insulin-like growth factor-1(IGF-1) and NAFLD. However, the results are controversial. This meta-analysis, aimed to systemically evaluate the correlation between IGF-1 and NAFLD. METHODS: We searched for four online databases: PubMed, Web of Science, Embase and CNKI up to Feb 2018. We then applied a random-effects model to evaluate the overall effect sizes by calculating Standard mean difference (SMD) and its 95% confidence intervals (CIs). RESULTS: Twelve articles were included in this meta-analysis. The pooled analysis showed that the level of IGF-1 in the control group was significantly higher than that in the NAFLD group. (SMD: 1.00, 95% CI: 0.54-1.46, P < 0.00001). However, significant heterogeneity was discovered among the included studies (P < 0.00001, I2 = 96%). Then a series of subgroup analyses were performed. Compared to the nonalcoholic steatohepatitis (NASH) group, the level of IGF-1 was significantly higher in the Non- or probable-NASH group (SMD: 1.42, 95% CI: 0.25-2.58, P = 0.02). The level of IGF-1 in patients with increased insulin resistance (SMD: 0.49; 95% CI: 0.36-0.63; P < 0.00001) and high Body Mass Index (SMD: 0.50; 95% CI: 0.22-0.79; P < 0.05) were significantly lower than healthy control. In addition, the same conclusion were found in studies carried out in Asia and Europe (Asia: SMD: 0.69, 95% CI: -0.29-1.66, P = 0.17; Europe: SMD: 0.89, 95% CI: 0.41-1.38, P < 0.05). CONCLUSION: The level of IGF-1 is down-regulated in NAFLD patients compared to healthy controls, suggesting that IGF-1 might be used as a potential biomarker and therapeutic target for NAFLD.
Authors: Ana Lúcia Farias de Azevedo Salgado; Luciana de Carvalho; Ana Claudia Oliveira; Virgínia Nascimento dos Santos; Jose Gilberto Vieira; Edison Roberto Parise Journal: Arq Gastroenterol Date: 2010 Apr-Jun
Authors: Laura E Dichtel; Kathleen E Corey; Joseph Misdraji; Miriam A Bredella; Melanie Schorr; Stephanie A Osganian; Brian J Young; Joshua C Sung; Karen K Miller Journal: Clin Transl Gastroenterol Date: 2017-01-26 Impact factor: 4.488
Authors: Marc-Olivier Deguise; Chantal Pileggi; Yves De Repentigny; Ariane Beauvais; Alexandra Tierney; Lucia Chehade; Jean Michaud; Maica Llavero-Hurtado; Douglas Lamont; Abdelmadjid Atrih; Thomas M Wishart; Thomas H Gillingwater; Bernard L Schneider; Mary-Ellen Harper; Simon H Parson; Rashmi Kothary Journal: Cell Mol Gastroenterol Hepatol Date: 2021-02-02
Authors: Jihad Aljabban; Michael Rohr; Saad Syed; Kamal Khorfan; Vincent Borkowski; Hisham Aljabban; Michael Segal; Mohamed Mukhtar; Mohammed Mohammed; Maryam Panahiazar; Dexter Hadley; Ryan Spengler; Erin Spengler Journal: World J Hepatol Date: 2022-07-27
Authors: María José Rodríguez; Matías Sabaj; Gerardo Tolosa; Francisca Herrera Vielma; María José Zúñiga; Daniel R González; Jessica Zúñiga-Hernández Journal: Cells Date: 2021-12-03 Impact factor: 6.600